Dan Merz Joins St. Jude Medical as Director, Clinical Affairs


ATLANTA, Georgia – March 14 2013

Life Science Partner announces the recruitment of Dan Merz to become Director, Clinical Affairs for St. Jude Medical. Merz is an innovative engineer who has created teams and processes to improve the speed of clinical development and product approval in the US and Japan.

Merz’s leadership capabilities will serve him well in his new role as Director, Clinical Affairs at St. Jude Medical, where he will have the responsibility for clinical trial monitoring, budget and clinical trial agreement process, as well as the responsibility for directly leading the teams accountable for the clinical program activities for the Portico TVH valve studies.

In his most recent role, Merz served as Director, Clinical and Regulatory Affairs for American Medical Systems (AMS) where he led the organizational redesign of AMS clinical research executive teams to align with Endo Pharmaceuticals. Since the realignment of the clinical organizations, Merz launched 292 patient randomized trials in Europe with 30 sites involving 11 nations.

“Merz is an articulate leader who has motivated teams to overcome regulatory hurdles and as to provide new tools for physicians to treat their patients,” noted Tom Callaway, MD, founder of Life Science Partner. “He has successfully built and led clinical organizations to move an innovative technology to the market.”

Merz earned his Bachelor of Science Degree in Biomedical Engineering at Northwestern University.


Recruiting Transformational Leaders™

Life Science Partner is a specialized executive search firm that recruits transformational leaders for healthcare and life sciences companies. Our high-touch, partner-led process ensures an exceptional level of service, while our backgrounds as physicians and industry executives enable us to efficiently deliver the brightest candidates in the medical device, biopharmaceuticals, diagnostics, and healthcare technology fields.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply